The Lead Episode 24: A Discussion of Catheter Ablation in End-Stage Heart Failure with Atrial Fibrillation

Description

William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by Kolade Muchaili Agboola, MD, and Akshay Suvas Desai, MD, MPH, of Brigham and Women's Hospital to discuss the results and implications of the CASTLE-HTx trial.

Learning Objectives

To understand the methods and results of the CASTLE-HTx trial
To recognize the limitations of the CASTLE-HTx trial and how the trial contributes to our understanding of the role of ablation for the management of atrial fibrillation in patients with severe HF.

Article Authors and Podcast Contributors

Article Authors
Sohns C, Fox H, Marrouche NF, Crijns HJ, Costard-Jaeckle A, Bergau L, Hindricks G, Dagres N, Sossalla S, Schramm R, Fink T, on behalf of the CASTLE-HTx Investigators

Podcast Contributors
William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital
Kolade Muchaili Agboola, MD, of Brigham and Women’s Hospital
Akshay Suvas Desai, MD, MPH, of Brigham and Women's Hospital

Disclosures

All relevant financial relationships have been mitigated.

Host Disclosure(s):
W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic

Contributor Disclosure(s):
K. Agboola: No relevant financial relationships with ineligible companies to disclose.
A. Desai: Honoraria/Speaking/Consulting Fee: Abbott, Novartis, AstraZeneca, BioFourmis, Regeneron, Alnylam Pharmaceuticals, Bayer Healthcare Pharmaceuticals, Cytokinetics, AxonTherapies, Avidity Biosciences, Medpace, Merck, New Amsterdam Pharma, Parexel, Roche Diagnostics, GlaxoSmithKline, NovoNordisk, Veristat, Verily/Google, Zydus, River2Renal; Research (Contracted Grants for PIs Named Investigators Only): Bayer Healthcare Pharmaceuticals, Abbott Medical, AstraZeneca, Novartis

Staff Disclosure(s) (note: HRS staff are NOT in control of educational content. Disclosures are provided solely for full transparency to the learner):
J. Glenn: No relevant financial relationships with ineligible companies to disclose.
S. Sailor: No relevant financial relationships with ineligible companies to disclose.

Summary


Availability:	On-Demand


Cost:	FREE


Credit Offered:	No Credit Offered

Recommended

The Lead Episode 1: A Discussion of Left Bundle Branch Area Pacing Versus Biventricular Pacing as the Initial Implant Strategy for Cardiac Resynchronization Therapy

No Credit

FREE

Warren Jackman's Art of War: A Sniper's Approach to Catheter Ablation

No Credit

FREE

(8)

The Lead Episode 77: A Discussion of Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation

No Credit

FREE

The Beat Webinar Series - Episode 10 - Understanding the FDA's Role in Regulating Medical Devices & The Role of Practicing Clinicians in the Device Surveillance Process (On Demand)

Multiple Credits

FREE

(8)

The Lead Episode 14: A Discussion of A Dual-Chamber Leadless Pacemaker

No Credit

FREE

The Beat Webinar Series - Episode 8 - LIVE from New Orleans, Cases of Genetic Arrhythmias (On Demand)

No Credit

FREE

(2)

The Beat Webinar Series - Episode 7 - Sudden Cardiac Death: What you need to Know (On Demand)

No Credit

FREE

The Beat Webinar Series - Episode 6 - An Uncommon Case of Idiopathic Left Fascicular Tachycardia (On Demand)

Multiple Credits

FREE

(6)

The Beat Webinar Series - Episode 1 - Management of Electrical Storm

Multiple Credits

$25.00 - $50.00